Slaughter and May is advising Kosmos Energy on its proposed secondary listing on the standard segment of the London Stock Exchange. Kosmos is a leading independent oil and gas exploration and production company focused on frontier and emerging areas along the Atlantic Margin which has been listed on the New York Stock Exchange since its IPO in 2011.

Kosmos is pursuing a listing on the London Stock Exchange to broaden its international investor base. The listing is expected to become effective in the third quarter of 2017.

Contacts

Herbert Smith Freehills is advising Yancoal Australia Ltd (Yancoal) on its US$2.5 (A$3.1) billion capital raising, which comprises a renounceable non-accelerated pro-rata Entitlement Offer (with rights trading) entitling eligible shareholders to 23.6 new shares for every 1 existing share held on the record date, and placement of new shares to institutional investors, at an offer price of US$0.10 ($A0.12) per share, announced to ASX on 2 August 2017.

NautaDutilh Luxembourg advised, alongside Latham & Watkins and Weil Gotshal, the underwriters JP Morgan, UBS and Bank of America Merrill Lynch, on the EUR 1 billion initial public offering (IPO) of Play on the Warsaw Stock Exchange, which values the company at EUR 4 billion (PLN 16 billion).

Play was listed on 27 July 2017. It is the largest IPO in the telecommunications sector in Europe since June 2015, and one of the five largest ever Polish IPO's. Play was assisted by White & Case and Loyens & Loeff.

We advised Greencoat Renewables on its initial public offering (IPO) and the admission to trading of its Ordinary Shares on AIM and ESM markets of the London Stock Exchange plc and Irish Stock Exchange plc.

Dentons advised the offering managers - including Haitong Bank, mBank, Pekao Investment Banking, Wood&Co, Raiffeisen Centrobank, Mercurius, Trigon and Vestor - on the initial public offering and listing on the Warsaw Stock Exchange (WSE) of the Polish debt collection company GetBack S.A. The company debuted on the primary market of the WSE on July 17, 2017.

Davis Polk advised Biotoscana Investments S.A. and the selling shareholders in connection with an initial public offering of 44,550,000 common shares, including common shares in the form of Brazilian Depositary Receipts, for an aggregate amount of approximately $377.7 million. The common shares trade on the Luxembourg Stock Exchange and the BDRs trade on the São Paulo Stock Exchange. The securities sold in the international offering were placed under Rule 144A and Regulation S.

Travers Smith LLP has advised long-standing client Harvey Nash Group PLC in relation to its transfer from the London Stock Exchange's main market for listed securities to trading on AIM.

Harvey Nash was established in 1988 and since then has supported many of the world's leading organisations to recruit, source and manage the highly skilled talent they need to succeed in an increasingly competitive and technology driven world.

The ECM team at CMS is advising on five IPOs which have launched in the last week:

    Andes Energia – £844m readmission to AIM following its reverse acquisition of Argentinian oil and gas exploration and production investor, Trefoil Holdings
    QUIZ - £200m AIM-IPO of the QUIZ clothing omni-channel fast fashion womenswear company
    Strix Group - £190m AIM-IPO of this global leader in the design, manufacture and supply of kettle safety controls and other components

Sidley represented the underwriters, including ICICI Securities Limited, HDFC Bank Limited, Motilal Oswal Investment Advisors Private Limited and Citigroup Global Markets India Private Limited, in a Section 4(a) and Regulation S initial public offering of AU Small Finance Bank. The total offering amount was approximately US$295 million.

Sidley represented Axis Capital Limited, Citigroup Global Markets India Private Limited and Credit Suisse Securities (India) Private Limited as underwriters in the Section 4(a) and Regulation S compliant initial public offering of Eris Lifesciences Limited. The total offering amount was approximately US$270 million. This offering is the largest pharmaceutical company IPO from India to date and one of the largest private exits ever by way of an IPO.